Terms: = Uterine cancer AND HRAS, K-ras, 3265, ENSG00000174775, HRAS1, RASH1, c-bas/has, P01112, N-ras AND Prognosis
33 results:
1. Comprehensive analysis of PHGDH for predicting prognosis and immunotherapy response in patients with endometrial carcinoma.
Zhang H; Kong W; Zhao X; Xie Y; Luo D; Chen S
BMC Med Genomics; 2023 Feb; 16(1):29. PubMed ID: 36803157
[TBL] [Abstract] [Full Text] [Related]
2. High expression of S100A2 predicts poor prognosis in patients with endometrial carcinoma.
Zhang Q; Xia T; Qi C; Du J; Ye C
BMC Cancer; 2022 Jan; 22(1):77. PubMed ID: 35042454
[TBL] [Abstract] [Full Text] [Related]
3. DUSP7 inhibits cervical cancer progression by inactivating the RAS pathway.
Bai H; Song M; Jiao R; Li W; Zhao J; Xiao M; Jin M; Zhang Z; Deng H
J Cell Mol Med; 2021 Oct; 25(19):9306-9318. PubMed ID: 34435746
[TBL] [Abstract] [Full Text] [Related]
4. Preoperative clinical characteristics scoring system for differentiating uterine leiomyosarcoma from fibroid.
Zhang G; Yu X; Zhu L; Fan Q; Shi H; Lang J
BMC Cancer; 2020 Jun; 20(1):514. PubMed ID: 32493236
[TBL] [Abstract] [Full Text] [Related]
5. Molecular approaches for classifying endometrial carcinoma.
Piulats JM; Guerra E; Gil-Martín M; Roman-Canal B; Gatius S; Sanz-Pamplona R; Velasco A; Vidal A; Matias-Guiu X
Gynecol Oncol; 2017 Apr; 145(1):200-207. PubMed ID: 28040204
[TBL] [Abstract] [Full Text] [Related]
6. Pathology of Endometrial Carcinoma.
Lax SF
Adv Exp Med Biol; 2017; 943():75-96. PubMed ID: 27910065
[TBL] [Abstract] [Full Text] [Related]
7. Chromosome aberrations [dup(1q)] in endometrial cancer: Gene analysis of 54 surgical specimens in Turkey.
Sever E; Döğer E; Kumbasar S; Şık BA; Temur M; Yılmaz HT; Yılmaz Ö; Özbay PO; Yücesoy İ
Taiwan J Obstet Gynecol; 2016 Jun; 55(3):357-62. PubMed ID: 27343315
[TBL] [Abstract] [Full Text] [Related]
8. Surgical treatment of high stage endometrial cancer: current perspectives.
Vitale SG; Valenti G; Gulino FA; Cignini P; Biondi A
Updates Surg; 2016 Jun; 68(2):149-54. PubMed ID: 26826083
[TBL] [Abstract] [Full Text] [Related]
9. Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative.
Stelloo E; Bosse T; Nout RA; MacKay HJ; Church DN; Nijman HW; Leary A; Edmondson RJ; Powell ME; Crosbie EJ; Kitchener HC; Mileshkin L; Pollock PM; Smit VT; Creutzberg CL
Mod Pathol; 2015 Jun; 28(6):836-44. PubMed ID: 25720322
[TBL] [Abstract] [Full Text] [Related]
10. Genome-wide single nucleotide polymorphism arrays as a diagnostic tool in patients with synchronous endometrial and ovarian cancer.
Ikeda Y; Oda K; Nakagawa S; Murayama-Hosokawa S; Yamamoto S; Ishikawa S; Wang L; Takazawa Y; Maeda D; Wada-Hiraike O; Kawana K; Fukayama M; Aburatani H; Yano T; Kozuma S; Taketani Y
Int J Gynecol Cancer; 2012 Jun; 22(5):725-31. PubMed ID: 22635024
[TBL] [Abstract] [Full Text] [Related]
11. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.
McCluggage WG
Pathology; 2011 Aug; 43(5):420-32. PubMed ID: 21716157
[TBL] [Abstract] [Full Text] [Related]
12. Effects of tamoxifen on the endometrium and its mechanism of carcinogenicity.
Yasue A; Hasegawa K; Udagawa Y
Hum Cell; 2011 Jun; 24(2):65-73. PubMed ID: 21547354
[TBL] [Abstract] [Full Text] [Related]
13. Genetic alterations in the k-ras gene influence the prognosis in patients with cervical cancer treated by radiotherapy.
Wegman P; Ahlin C; Sorbe B
Int J Gynecol Cancer; 2011 Jan; 21(1):86-91. PubMed ID: 21330833
[TBL] [Abstract] [Full Text] [Related]
14. Genome-wide single-nucleotide polymorphism arrays in endometrial carcinomas associate extensive chromosomal instability with poor prognosis and unveil frequent chromosomal imbalances involved in the PI3-kinase pathway.
Murayama-Hosokawa S; Oda K; Nakagawa S; Ishikawa S; Yamamoto S; Shoji K; Ikeda Y; Uehara Y; Fukayama M; McCormick F; Yano T; Taketani Y; Aburatani H
Oncogene; 2010 Apr; 29(13):1897-908. PubMed ID: 20062086
[TBL] [Abstract] [Full Text] [Related]
15. The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies.
Bansal N; Yendluri V; Wenham RM
Cancer Control; 2009 Jan; 16(1):8-13. PubMed ID: 19078924
[TBL] [Abstract] [Full Text] [Related]
16. Molecular pathology of endometrial carcinoma: practical aspects from the diagnostic and therapeutic viewpoints.
Llobet D; Pallares J; Yeramian A; Santacana M; Eritja N; Velasco A; Dolcet X; Matias-Guiu X
J Clin Pathol; 2009 Sep; 62(9):777-85. PubMed ID: 18977806
[TBL] [Abstract] [Full Text] [Related]
17. PIK3CA mutations in the kinase domain (exon 20) of uterine endometrial adenocarcinomas are associated with adverse prognostic parameters.
Catasus L; Gallardo A; Cuatrecasas M; Prat J
Mod Pathol; 2008 Feb; 21(2):131-9. PubMed ID: 18084252
[TBL] [Abstract] [Full Text] [Related]
18. Molecular carcinogenesis of endometrial cancer.
Liu FS
Taiwan J Obstet Gynecol; 2007 Mar; 46(1):26-32. PubMed ID: 17389185
[TBL] [Abstract] [Full Text] [Related]
19. p53 mutations and overexpression affect prognosis of ovarian endometrioid cancer but not clear cell cancer.
Okuda T; Otsuka J; Sekizawa A; Saito H; Makino R; Kushima M; Farina A; Kuwano Y; Okai T
Gynecol Oncol; 2003 Mar; 88(3):318-25. PubMed ID: 12648581
[TBL] [Abstract] [Full Text] [Related]
20. [Dualistic model of molecular pathogenesis in endometrial carcinoma].
Lax SF
Zentralbl Gynakol; 2002 Jan; 124(1):10-6. PubMed ID: 11873308
[TBL] [Abstract] [Full Text] [Related]
[Next]
